


# PRODUCT INFORMATION



**SB 218078**

Item No. 13335

**CAS Registry No.:** 135897-06-2  
**Formal Name:** 9,10,11,12-tetrahydro-9,12-epoxy-1H-diiindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione  
**MF:** C<sub>24</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>  
**FW:** 393.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 237, 278, 287, 318, 414 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

SB 218078 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 218078 in the solvent of choice, which should be purged with an inert gas. SB 218078 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of SB 218078 in these solvents is approximately 5 mg/ml.

SB 218078 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 218078 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SB 218078 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that blocks phosphorylation of Cdc25 with an IC<sub>50</sub> value of 15 nM.<sup>1</sup> It less potently inhibits Cdc2 and PKC (IC<sub>50</sub>s = 250 and 1,000 nM, respectively) and causes 85% inhibition of PKD1 at 1 μM.<sup>1,2</sup> SB 218078 releases G<sub>2</sub> cell cycle arrest induced by γ-irradiation or the topoisomerase I inhibitor topotecan (Item No. 14129).<sup>1</sup> In this way, SB 218078 enhances the cytotoxicity of DNA-damaging compounds.<sup>3</sup>

## References

1. Jackson, J.R., Gilmartin, A., Imburgia, G., *et al.* An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. *Cancer Res.* **60(3)**, 566-572 (2000).
2. Tandon, M., Johnson, J., Li, Z., *et al.* New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells. *PLoS One* **8(9)**, e75601 (2013).
3. Kawabe, T. G<sub>2</sub> checkpoint abrogators as anticancer drugs. *Mol. Cancer Ther.* **3(4)**, 513-519 (2004).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM